# Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

> **NCT00339183** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 1186 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT00339183
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-30
- **Primary completion:** 2009-04-01
- **Final completion:** 2010-11-01
- **Target enrollment:** 1186 (ACTUAL)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00339183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00339183, "Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00339183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*